Double-blind clinical evaluation of the efficacy and safety of ergostine-caffeine, ergotamine-caffeine, and placebo in migraine headache.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002110:Caffeine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004876:Ergot Alkaloids / Q000627:therapeutic use*; D004878:Ergotamine / Q000627:therapeutic use*; D005260:Female; D006261:Headache / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D010919:Placebos / Q000627:therapeutic use
D004876:Ergot Alkaloids; D010919:Placebos; D002110:Caffeine; D004878:Ergotamine